On June 17, 2024, Mangoceuticals, Inc. conducted its 2024 Annual Meeting of Stockholders, with a quorum achieved through the presence of 20,115,314 shares, against a total of 24,819,500 shares outstanding as of the record date, May 6, 2024. During the meeting, shareholders voted on six key proposals. The election of directors Jacob D. Cohen, Lorraine D’Alessio, Alex P. Hamilton, and Dr. Kenny Myers was confirmed. Additionally, the issuance of over 19.99% of outstanding common stock upon conversion of Series B Convertible Preferred Stock and certain warrants was approved, in compliance with Nasdaq Listing Rule 5635(d). Similar approval was granted for the issuance of stock pursuant to an Equity Purchase Agreement and for the full issuance of shares related to the 6% Series C Convertible Cumulative Preferred Stock. Turner, Stone & Company, L.L.P. was appointed as the independent auditors for the fiscal year ending December 31, 2024. A proposal to adjourn the meeting for additional proxy solicitation was also approved, but the adjournment was not necessary.

On June 17, 2024, Mangoceuticals, Inc. conducted its 2024 Annual Meeting of Stockholders, with a quorum achieved through the presence of 20,115,314 shares, against a total of 24,819,500 shares outstanding as of the record date, May 6, 2024. During the meeting, shareholders voted on six key proposals. The election of directors Jacob D. Cohen, Lorraine D’Alessio, Alex P. Hamilton, and Dr. Kenny Myers was confirmed. Additionally, the issuance of over 19.99% of outstanding common stock upon conversion of Series B Convertible Preferred Stock and certain warrants was approved, in compliance with Nasdaq Listing Rule 5635(d). Similar approval was granted for the issuance of stock pursuant to an Equity Purchase Agreement and for the full issuance of shares related to the 6% Series C Convertible Cumulative Preferred Stock. Turner, Stone & Company, L.L.P. was appointed as the independent auditors for the fiscal year ending December 31, 2024. A proposal to adjourn the meeting for additional proxy solicitation was also approved, but the adjournment was not necessary.